Michael R. Cooper

Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin

José Baselga, David G. Pfister, Michael R. Cooper et al. · Journal of Clinical Oncology · 2000 · 746 citations

Pharmacy, Oncology, Pharmacology +17

Phase I Study of Anti–Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer

Francisco Robert, Mark P. Ezekiel, Sharon A. Spencer et al. · Journal of Clinical Oncology · 2001 · 473 citations

Medicine, Oncology, Pharmacology +16

Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.

Alain Thibault, Dvorit Samid, A Tompkins et al. · PubMed · 1996 · 361 citations

Medicine, Oncology, Pharmacology +10

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

Daniel J. DeAngelo, Richard M. Stone, Mark Heaney et al. · Blood · 2006 · 275 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.

Christopher D. Myers, Michael R. Cooper, C.A. Stein et al. · Journal of Clinical Oncology · 1992 · 237 citations

Medicine, Oncology, Pharmacology +12